IP Library Granted Patent US 10,265,397
Granted Patent B2
US 10,265,397 · App. 15/805,491 · Granted Apr 23, 2019

Formulation for photodynamic therapy

Inventors: Stefan Welzig (Vienna, AT); Gregor Medinger (Sag Harbor, NY); Beate Kálz (Steinbrunn, AT); József Gungl (Agfalva, HU); Klaus Gerdes (Dusseldorf, DE); Werner Frantsits (Vienna, AT); Christina Abrahamsberg (Vienna, AT)
Assignee: SANOCHEMIA PHARMAZEUTIKA AG
A61K41/0057A61K9/0009A61K9/08A61K9/19A61K47/32A61K47/58A61K47/60A61N5/062A61N2005/0663
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,265,397
App. No.
15/805,491
Granted
Apr 23, 2019
Kind
B2
Abstract

Photodynamic therapy of tumors such as bladder tumors includes photosensitizing with a photosensitizer that is a complex or a compound of hypericin and a polymeric complexing agent. The photosensitizer is formed from an alkali salt of hypericin and the polymeric complexing agent. The alkali salt of hypericin is a sodium salt or a potassium salt. The complexing agent is a polyethylene glycol or a poly-N-vinyl amide.

Claims (3)

1. A formulation for photodynamic therapy, comprising: a photosensitizer that is a stable complex or a stable compound of a sodium or potassium salt of hypericin and a polymeric complexing agent selected from the group consisting of polyethylene glycol and poly-N-vinyl amide, wherein the photosensitizer is obtained from a lyophilisate obtained from a solution of the sodium or potassium salt of hypericin, containing 0.0225 mg hypericin/g solution, the polymeric complexing agent and a buffer system comprising a phosphate buffer or a citric acid buffer.

2. The formulation according to claim 1 , wherein the poly-N-vinyl amide is a polyvinylpyrrolidone (PVP) of various degrees of polymerization and cross-linking.

3. The formulation according to claim 2 , wherein the polyvinylpyrrolidone is PVP k17, PVP k25 or PVP k30.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 9, 2020
From: SANOCHEMIA PHARMAZEUTIKA AG
To: SANOCHEMIA PHARMAZEUTIKA GMBH
Reel/Frame 053724/0617 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 7, 2017
From: WELZIG, STEFAN; MEDINGER, GREGOR; KALZ, BEATE; GUNGL, JOZSEF; GERDES, KLAUS; FRANTSITS, WERNER; ABRAHAMSBERG, CHRISTINA
To: SANOCHEMIA PHARMAZEUTIKA AG
Reel/Frame 044052/0955 →
Priority Claims (1)
AT 630/2015 · Sep 28, 2015 · national
Continuity (2)
Division 14878515 · Oct 8, 2015
Related Publication 20180055934A1 · Mar 1, 2018